Related Experiment Video

Updated: Aug 8, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes

Jana Ortmann1, Philipp C Nett, Jennifer Celeiro

  • 1Medical Policlinic, Department of Internal Medicine, University Hospital Zürich, Switzerland.

Experimental Biology and Medicine (Maywood, N.J.)
|June 3, 2006
PubMed

Insights

Early autoimmune diabetes downregulates kidney endothelin-converting enzymes (ECEs) and prepro-endothelin-1 (ET-1). Blocking ET(A) receptors delays diabetes onset and normalizes gene expression in mice.

Area of Science:

  • Endocrinology
  • Nephrology
  • Immunology

Background:

  • Autoimmune diabetes, such as type 1 diabetes, involves complex interactions between the immune system and metabolic processes.
  • The endothelin system, including endothelin-converting enzymes (ECEs) and endothelin (ET) peptides, plays a role in kidney function and vascular regulation.
  • Dysregulation of the endothelin system has been implicated in various kidney diseases and metabolic disorders.

Purpose of the Study:

  • To investigate the impact of early-stage autoimmune diabetes on renal expression of ECEs and ET.
  • To determine the involvement of endothelin A (ET(A)) receptors in these early changes.
  • To evaluate the therapeutic potential of ET(A) receptor antagonism in delaying autoimmune diabetes onset.

Main Methods:

  • Prediabetic nonobese diabetic (NOD) mice and control mice were treated with an ET(A) receptor antagonist (BSF461314) or placebo.
  • Renal gene expression of ECE-1, ECE-2, and prepro-ET-1 was quantified using real-time polymerase chain reaction.
  • Blood glucose levels and renal histology were assessed.

Main Results:

  • NOD mice exhibited reduced renal expression of ECE-1, ECE-2, and prepro-ET-1 compared to controls, despite normal renal histology.
  • Treatment with the ET(A) receptor antagonist BSF461314 delayed the onset of diabetes in NOD mice.
  • The antagonist treatment also increased the expression of ECE-1, ECE-2, and prepro-ET-1 in NOD mice.

Conclusions:

  • Early hyperglycemia in autoimmune diabetes is associated with decreased renal expression of ECE-1, ECE-2, and prepro-ET-1.
  • ET(A) receptor blockade demonstrates potential therapeutic benefits by inhibiting diabetes-associated gene dysregulation and delaying disease onset.
  • Targeting the endothelin system may offer a novel strategy for managing autoimmune diabetes.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...